These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1935 related articles for article (PubMed ID: 10342782)

  • 1. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
    Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
    Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease.
    Jensen J; Henik RA; Brownfield M; Armstrong J
    Am J Vet Res; 1997 May; 58(5):535-40. PubMed ID: 9140564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of angiotensin II to suppress plasma renin activity in normotensive subjects with a positive family history of hypertension.
    Herlitz H; Palmgren E; Widgren B; Aurell M
    Clin Sci (Lond); 2005 Sep; 109(3):311-7. PubMed ID: 15901242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone replacement therapy increases plasma level of angiotensin II in postmenopausal hypertensive women.
    Umeda M; Ichikawa S; Kanda T; Sumino H; Kobayashi I
    Am J Hypertens; 2001 Mar; 14(3):206-11. PubMed ID: 11281230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension.
    Bauer IH; Reams GP; Wu Z; Lau-Sieckman A
    J Hum Hypertens; 1995 Apr; 9(4):237-43. PubMed ID: 7595905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interruption of prolonged ramipril treatment in hypertensive patients: effects on the renin-angiotensin system.
    Stephan D; Grima M; Welsch M; Barthelmebs M; Vasmant D; Imbs J
    Fundam Clin Pharmacol; 1996; 10(5):474-83. PubMed ID: 8902551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the renin-angiotensin-aldosterone system on blood pressure response to intravenous enalaprilat in patients with hypertensive crises.
    Hirschl MM; Binder M; Bur A; Herkner H; Woisetschläger C; Bieglmayer C; Laggner AN
    J Hum Hypertens; 1997 Mar; 11(3):177-83. PubMed ID: 9175570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
    Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
    Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension.
    Browne GA; Griffin TP; O'Shea PM; Dennedy MC
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):325-31. PubMed ID: 26300226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin and beta-blockade: prorenin and aldosterone may explain the controversy.
    McKenna F; Davison AM
    Clin Nephrol; 1986 Mar; 25(3):149-54. PubMed ID: 2869848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of high-performance liquid chromatography on plasma angiotensin II measurements in treated and untreated normotensive and hypertensive patients.
    Bragat AC; Blumenfeld J; Sealey JE
    J Hypertens; 1997 May; 15(5):459-65. PubMed ID: 9169997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of telmisartan on blood pressure, the renin-angiotensin-aldosterone system, and lipids in hypertensive patients.
    Aoki A; Ogawa T; Sumino H; Kumakura H; Takayama Y; Ichikawa S; Nitta K
    Heart Vessels; 2010 May; 25(3):195-202. PubMed ID: 20512446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats.
    Jessup JA; Gallagher PE; Averill DB; Brosnihan KB; Tallant EA; Chappell MC; Ferrario CM
    Am J Physiol Heart Circ Physiol; 2006 Nov; 291(5):H2166-72. PubMed ID: 16766648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
    Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
    Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
    Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
    Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system.
    Schalekamp MA; Derkx FH; van den Meiracker AH
    J Hypertens Suppl; 1992 Dec; 10(7):S157-64. PubMed ID: 1291650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
    Nussberger J; Wuerzner G; Jensen C; Brunner HR
    Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma renin activity to plasma aldosterone concentration ratio correlates with night-time and pulse pressures in essential hypertensive patients treated with angiotensin-converting enzyme inhibitors/AT1 blockers.
    Spannella F; Giulietti F; Balietti P; Borioni E; Lombardi FE; Ricci M; Cocci G; Landi L; Sarzani R
    J Hypertens; 2017 Nov; 35(11):2315-2322. PubMed ID: 28614094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects.
    Lachurié ML; Azizi M; Guyene TT; Alhenc-Gelas F; Ménard J
    Circulation; 1995 Jun; 91(12):2933-42. PubMed ID: 7796503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 97.